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Objectives . This study investigated whether substance P poten-
tiates the muscular and cardiac pain caused by the intraarterial
infusion of adenosine, an autocoid known to induce muscular and
cardiac ischemic-like pain in humans .
Background. Substance P is involved in the generation of
neurogenic inflammation and causes cutaneous hyperalgesia . Be-
cause substance P is present in perivascular nerves it might also
cause muscular and cardiac hyperalgesia. To test this hypothesis
its effects on adenosine-induced muscular and cardiac pain were
Investigated in humans .
Methods. A randomized, crossover study of the algogenic
effects of the intraillac infusion of increasing scalar doses (from
125 to Q* pg%0 of adenosine or substance P (1L2 pmollmin)
for 3 min, followed by the simultaneous infusion of substance P
plus the same doses of adenosine, was carried out in nine patients
with no evidence of peripheral vascular disease . A similar protocol
was carried out by infusing increasing scalar doses of adenosine
(from 50 to 800
lag/min)
or substance P (11 .2 pmol/min) for 3 min,
followed by the simultaneous infusion of substance P plus the same
doses of adenosine, into the left coronary artery of eight patients
Substance P is an 11-amino acid neuropeptide widely dis-
tributed in the central and peripheral nervous system (1) .
Substance P-like immunoreactive nerve fibers have been
found in the atrium, in the conduction tissue and in the
perivascular sensory nerves of many mammalian species,
including humans (2,3) . Since its discovery, substance P has
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with angina. Pain severity, assessed by a visual analog scale, is
presented as median . The remaining data are presented as mean
value ± 1 SD.
Remits . All patients experienced pain during both adenosine
and substance P plus adenosine infusion ; no patient experienced
pain during the infusion of substance P alone . Daring intraigac
infusion, all patients experienced pain in the right leg that
occurred earlier (207 ± 152 vs . 321 ± 154 s, p < 0.05) and was
greater (47 vs. 30 mm, p < 0.05) during the simultaneous infusion
of substance P plus adenosine than during the infusion of adeno-
sine. Similarly, during intracoronary infusion, all patients expe-
rienced chest pain that occurred earlier (W ± 242 vs . 596 :l:
210 s, p < 106) and was greater (51 vs . 33 mm, p < 0.05) during
the simultaneous infusion of substance P plus adenosine than
during infusion of adenosine . No patient exhibited electrecardio-
graphic signs of ischemia .
Conclusions. Substance P does not cause muscular or cardiac
pain, but it provokes muscular and cardiac hyperalgesia .
(J Am Coil Cardiol 1994;24:477 d2)
received considerable attention with regard to the generation
and transmission of nociceptive signals (4). Previous exper-
imental and clinical studies have emphasized the potential
role of substance P released from peripheral cutaneous nerve
terminals in the generation of hyperalgesia, that is, a lower-
ing of the pain threshold localized in an area of tissue damage
(5,6) . The intraarteriat infusion of substance P does not
appear to cause pain (7-11)
; however, it may cause hyper-
algesia. This study investigated whether substance P poten-
tiates the known algogenic
: effects caused by the intraarterial
infusion of adenosine (12-15) .
Methods
The study protocols were approved by the Institutional
Ethics Committee in March 1992, and all patients gave written
informed consent .
Adenosine and substance P preparation . Adenosine
(2.7 mglml in ampules of 2 ml) (Sigma Tau Pharmaceutics)
0735-10971941$7 .00
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Figm l . Diagrammatic representation of the infusion protocols for
both intrailiac and intracoronary studies . Pro 1 : Adenosine was
infused at increasing doses for periods of 2 (during intrailiac study)
or 3 (during intracoronary study) min each . At the onset of pain,
adenosine infusion was continued to complete the infusion period of
that particular dose of adenosine . Infusion of adenosine was then
stopped . Ten minutes after the disappearance of adenosine-induced
pain, substance P alone was infused for 3 min, followed by the
simultaneous infusion of increasing doses of adenosine . At onset of
pain, adenosine plus substance P infusion was continued to com-
plete the infusion period of that particular dose of adenosine .
Infusion of adenosine plus substance P was then stopped . Prutocel 2 :
Substance P alone was infused for 3 min followed by simultaneous
infusion of increasing doses of adenosine. At onset of pain, adeno .
sine plus substance P infusion was continued to complete the
infusion period of that particular dose of adenosine . Infusion of
adenosine plus substance P was then stopped . Ten minutes after the
disappearance of pain . adenosine alone was infused at increasing
doses for periods of 2 (during intrailiac study) or 3 (during intracor-
onary study) min each . At onset of pain, adenosine infusion was
continued to complete the infusion period of that particular dose of
adenosine . The infusion of adenosine was then stopped .
was stored at -60°C and was dissolved in normal saline
solution to the final concentrations on the day of the study .
Substance P (Cambridge Research Biochemicals) was dis-
solved in
111, acetic acid to a concentration of 1 mmollliter,
diluted further with normal saline solution to a stock solution
of 2 x 10
-4
mol/liter, and stored at -60°C . All further
dilutions were prepared on the day of the study using normal
saline solution . A matched stock solution of the acetic acid
without substance P was also prepared and stored at -60°C .
Further dilutions corresponding to that made for the prepa .
ration of substance P (11 .2 pmol) were made with normal
saline solution on the day of the study for the control
infusion . Substance P solution and the vehicle were not
additionally buffered.
y. A total of 18 consecutive male patients
(mean (±SD] age 54 ± 9 years, range 37 to 70) with no
evidence of peripheral vascular disease (ankle/brachial index
> I assessed by vascular Doppler) participated in this study .
At the end of routine cardiac catheterization, nine patients
underwent a randomized crossover study of the algogenic
effects of the infusion of adenosine or the simultaneous
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infusion of substance P plus adenosine into the right external
iliac artery by means of a 5F catheter (Fig. 1) . In all patients
the 5F catheter was inserted through a 7F femoral sheath .
Adenosine was infused at increasing doses of 125, 250, 500,
1, and 2, pg1min for periods of 2 rein each . Substance
P alone (11 .2 pmol/min) was infused at the rate of 2 milmin
for 3 min, followed by the simultaneous infusion of sub-
stance P (11 .2 pmollmin) plus the same doses of adenosine .
At the onset of pain the infusion of adenosine or substance P
plus adenosine was continued to complete the infusion
period of that particular dose of adenosine and was then
stopped. The time to onset of pain (in seconds from the
beginning of the infusion) and maximal pain severity, as-
sessed by using a visual analog scale (16), were recorded .
Five patients received adenosine ; four patients received
substance P plus adenosine as first infusion . Arterial blood
pressure, obtained by way of the side port of the fertoral
sheath, and the standard 12 electrocardiographic (ECG)
leads were recorded continuously throughout the study .
Nine other male patients (mean age 51 years, range 41 to
63) served as a control group. They received the inirailiac
infusion of adenosine and the simultaneous infusion of
substance P vehicle plus adenosine using the same protocol
specified previously . Five patients received adenosine,
whereas four received substance P vehicle plus adenosine as
first infusion .
Intracoro study. Eight patients (seven men, one
woman; mean age 58 years, range 44 to 65) with stable
angina pectoris and significant left coronary atherosclerosis
participated in this study . No patient had a previous myo-
cardial infarction . All patients had exercise tests pcsitive for
myocardial ischemia with horizontal or downsloping ST
segment depression X2 .0 mm and anginal pain . All patients
had at least one significant coronary artery stenosis (internal
diameter reduction >7017o by visual assessment) . In particu-
lar, three patients had significant stenosis in the left anterior
descending coronary, three patients had stenosis in the
proximal circumflex coronary artery, and two patients had
significant lesions in both arteries . All patients were normo-
tensive, in sinus rhythm and without evidence of heart
failure, cardiomyopathy or valvular disease . Patients with a
JACC Voi . 24. No . 2
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history of glucose intolerance were excluded from the study .
No patient had evidence of left ventricular hypertrophy or
conduction defects that could interfere with the interpreta-
tion of ST segment changes, and no patient was taking
digitalis . Calcium channel blocking and beta-adrenergic
blocking agents were withdrawn 2 days before the study .
Patients were also requested to abstain from xanthine-
containing drugs and food and drink for at least 48 h before
study . Ofl completion of the diagnostic angiograms of both
coronary arteries, te left coronary artery was recannulated
with a SF left Judkins catheter of appropriate size . Patients
then underwent a randomized crossover study of the algo-
genic effects of the infusion of adenosine or the simultaneous
infusion of substance P plus the same doses of adenosine
into the left coronary artery (Fig . 1) . Adenosine was infused
at increasing scalar doses of 50, 100, 200, 400 and 800 jLgimin
for periods of 3 min each until the occurrence of pain .
Substance P alone (11 .2 pmollmin) was infused at the rate of
2 ml/min for 3 min, followed by the simultaneous infusion
of substance P (11 .2 pmollmin) plus the same doses of
adenosine reported previously . At the onset of pain the
infusion of adenosine or of substance P plus adenosine was
continued to complete the infusion period of that particular
dose of adenosine and was then stopped . Time to the onset
of pain (in seconds from the beginning of the infusion) and
maximal pain severity assessed by using a visual analog
scale (16) were recorded . Four patients received adenosine ;
four patients received substance P plus adenosine as first
infusion. Arterial blood pressure, obtained by way of the
side port of the 7F femoral sheath, and the standard 12 ECG
leads were continuously recorded throughout the study .
Assessment of pain. At the beginning of each adenosine
or substance P plus adenosine infusion, patients were in-
formed that they might experience pain or other unpleasant
symptoms. This was not repeated during the infusion of
adenosine or of substance P plus adenosine to avoid any
potential bias . Patients were also instructed to report
promptly the onset of pain and to record the maximal
severity of the pain . Immediately after the test, while the
patients were still in the catheterization laboratory, they
were asked to report the maximal severity of pain using a
visual analog scale (16) . To this end the 100-mm scale was
marked from no symptoms to severe symptoms . The scale
was measured from zero to the subject's mark in millimeters .
All subjects were unaware of the nature of the infused
materials. Testing personnel were aware of the nature of the
infused materials .
Statistical analysis. Statistical analysis of the hemody-
namic data was performed using analysis of variance. The
Student i test for paired data was used to compare the time
to pain onset. Pain severity was analyzed with the Wilcoxon
signed rank-sum test because this variable does not have a
normal distribution. Visual analog scale data are expressed
as median and range values . The remaining data are pre-
sented as mean value ± I SD . For purposes of this study,
p < 0.05 was considered significant .
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Figure 2 . Effect of intrailiac artery infusion of adenosine alone and
substance P (SP) plus adenosine on the time to onset of pain .
Results
Intrailiac infusion study . No patient experienced pain,
discomforIt or unpleasant symptoms during the infusion of
substance P alone . Conversely, all patients experienced pain
localized to the right leg during the infusion of both sub-
stance P plus adenosine and adenosine . Six patients dc-
scribed the pain as a feeling of heaviness localized at the
right leg, and three patients experienced it as a cramp . In
all patients time to onsett of pain was shorter (207 ± 152 vs .
321 ± 154 s, p < 0.05) and pain severity was greater (47 mm
[range 30-100] vs . 30 mm [range 21-70], p < 0 .05) during
simultaneous infusion of substance P plus adenosine than
during adenosine infusion (Fig . 2 and 3) . The type of pain
during infusion of adenosine or substance P plus adenosine
was similar . The pain disappeared spontaneously within 60 s
of the end of infusion in all patients . Compared with baseline
values, no patient exhibited ECG changes or changes in
heart rate or mean arterial blood pressure during infusion of
adenosine alone, substance P alone or substance P plus
adenosine (73 ± 14 vs . 74 ± 13 vs . 72 ± 12 vs. 74 ± 13
beats/min, p = NS ; 103 ± 10 vs. 103 ± 8 vs . 101 ± 10 vs .
100 ± 12 mm Hg, p = NS, respectively) .
No patient experienced either pain or discomfort during
infusion of the vehicle solution alone . All patients experi-
enced pain localized to the right leg during infusion of both
Figure 3 . Effect of the intrailiac artery infusion of adenosine alone
and substance P (SP) plus adenosine on pain seventy .
adenosine
SP
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e 4. Effect of the intracoronary infusion of adenosine alone
ubstance P (SP) plus adenosine on the time to onset of pain .
substance P vehicle plus adenosine and adenosine alone .
Five patients described the pain as a feeling of heaviness,
and four patients experienced it as a cramp. In all patients
time to onset of pain (331 ± 134 vs . 314 ± 155 s . p am NS) and
pain severity (35 mm [range 20 to 711 vs . 30 mm [range 21 to
78], p = NS) were similar during both infusion of substance
P vehicle plus adenosine and adenosine infusion . The type of
pain during infusion of substance P vehicle plus adenosine or
adenosine was similar. Pain disappeared spontaneously
within 60 s of the end of infusion in all patients . Compared
with baseline values, no patient exhibited ECG changes or
changes in heart rate or mean arterial blood pressure during
infusion of adenosine alone, substance P alone or substance
P plus adenosine (72 ± 11 vs . TO ± 9 vs. 70 ± 9 vs . 71 ± 7
beatifnin, p gm NS; 103 ± 10 vs . 102 ± 11 vs . 115 ± 11 vs .
103 ± 9 mm Hg, p = NS, respectively) .
IntracoromM infusion study. No patient experienced
pain during intracoronary infusion of substance P alone . All
patients experienced pain similar to their usual anginal pain
during the infusion of both substance P plus adenosine and
adenosine . In all patients onset of pain occurred earlier
(40 ± 242 vs. 596 ± 210 s, p < 0.05) and pain severity was
greater (51 mm [range 21 to 69] vs . 33 mm [range 9 to 52],
p < 0.05) during simultaneous infusion of substance P plus
adenosine than during infusion of adenosine (Fig. 4 and 5) .
The type of pain during infusion of substance P plus adeno-
sine or adenosine was similar. Pain disappeared within 60 s
of the end of infusion in all patients . Compared with baseline
values, no patient exhibited ECG changes or changes in
heart rate
or mean arterial blood pressure during infusion of
adenosine alone, substance P alone or substance P plus
adenosine (70 ± 16 vs . 71 ± 19 vs
. 71 ± 16 vs . 69 ± 13
beats/min, p = NS; 99 ± IS vs. 98 ± 16 vs . 100 ± 17 vs . 99
16 mm Hg, p = NS, respectively) .
EDRinumulion
This study confirms that intraarterial infusion of sub-
stance P in humans does not cause pain (7-11). More
important, our results show that substance P potentiates the
MM IGO
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0
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Figure 5. Effect of the intracoronary infusion of adenosine alone
and substance P (SP) plus adenosine on pain severity .
algogenic effects of adenosine, thus suggesting that sub-
stance P causes muscular and cardiac hyperalgesia .
Role of substance P in modulation of peripheral algogenic
stimuli . Since the discovery of substance P by von Euler
and Gaddum in 1931 (17), considerable attention has been
devoted to its involvement in the generation or transmission,
or both, of nociceptive signals (4,18) . Substance P has been
implicated in the chemical activation of peripheral nocicep-
tive neurons and in their sensitization, leading to primary
hyperalgesia, that is, a localized lowering of the threshold to
pain in an area of tissue damage (5,6,19-22) . In the skin,
substance P released from the peripheral nerve terminals,
activated by tissue damage, induces several events leading
to neurogenic inflammation (6) . Indeed, substance P evokes
changes in vascular caliber and permeability, releases a
relaxant factor from vessel endothelium and stimulates the
release of inflammatory mediators, such as interleukins,
histamine, tissue necrosis factor and arachidonic acid
(6,21,23-25), which, in turn, by stimulating the nerve termi-
nals, may lead to further substance P release, thus causing a
"positive feedback" circuit between the sensory neurons
and the inflammatory cells (6) . In this setting, the primary
hyperalgesia caused by substance P might represent a pro-
tective mechanism by which subliminal stimuli can evoke
pain.
Evidence of the involvement of substance P in the pro-
duction of pain in humans is still circumstantial . In healthy
volunteers and in patients with atopic dermatitis, the topical
application of substance P evokes dose-dependent wheal,
flare and itch reactions (23) that are partially due to hista-
mine and cyclooxygenase products released from mast and
other inflammatory cells (24,25) . In patients with chronic
pancreatitis, a significant intensification of the immunostain-
ing for substance P was found in the peptidergic inlralobular
and interlobular nerves (26), suggesting that this peptide
might be responsible for the long-lasting pain syndrome in
chronic pancreatitis. Furthermore, substance P appears to
facilitate pain perception by sensitizing peripheral nerve
terminals to a variety of pain-producing agents. The injection
of calcitonin gene-related peptide into the temporal muscle
JMT VU 24, No 2
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of human volunteers does not induce more pain than pla-
cebo; however, when calcitonin gene-related peptide is
injected in combination with substance P, a significantly
more intense pain sensation is recorded (27) . Similarly, the
injection of bradykinin in the temporal muscle does not
provoke more pain than saline solution, but the simultaneous
injection of substance P and bradykinin significantly in-
creases pain sensation and lowers the pressure pain thresh-
old (28) . Finally, whereas the cutaneous injection of neuro-
kinir. A does not produce pain, the simultaneous injection of
substance P and neurokinin A provokes a painful sensation
(29) .
Interaction between adenosine and substance P in the
genesis of muscular and cardiac pain . Adenosine, a major
mediator of ischemic pain in humans (12-15), has been
shown to stimulate cardiac afferent fibers in experimental
models (30-32). Local ischemiclike pain can be provoked by
adenosine injection into the brachial or iliac artery (13,33) .
Intracoronary administration of adenosine in patients with
ischemic heart disease elicits angina pectoris-like pain,
which is described as indistinguishable from their habitual
anginal pain (14,15) . In the present study intrailiac and
intracoronary infusion of substance P facilitated adenosine-
induced pain, suggesting an interaction between these two
substances, perhaps at the level of muscalar and cardiac
nociceptors. The mechanism of this interaction cannot be
deduced from the current study . One possibility is that it
may result from a direct hyperalgesic effect of substance P
on muscular and cardiac nociceptors . Alternatively, it might
be due to substance P-mediated release of agents, such as
protons, 5-hydroxytryptamine, bradykinin, histamine, pros-
taglandins and nitric oxide, which, in turn, would be directly
responsible for the hyperalgesia (6,19-22) . Finally, a central
mechanism of hyperalgesia, such as sensitization of dorsal
horn spinothalamic neurons (21) or an action at the level of
substantia gelatinosa or thalamus, cannot be excluded . This
seems unlikely, however, because no systemic hemody-
namic effects were seen in our study during infusion of
adenosine or substance P plus adenosine . It is also theoret-
ically possible that the increased pain severity observed
during simultaneous infusion of substance P plus adenosine
might be attributable to an additional vasodilating effect of
substance P, thus allowing wider distribution of adenosine .
This possibility, however, is unlikely for the following rea-
sons: First, substance P is a much less powerful vasodilator
of the coronary resistance vessels than adenosine (7.8).
Second, the simultaneous intraarterial infusion of adenosine
and nifedipine, a potent vasodilator, does not potentiate the
algogenic effects of adenosine (33) . Finally, barniphylline, a
selective antagonist of A, adenosine receptors (34), prevents
pain induced by intracoronary infusion of adenosine, but not
the coronary vasodilator response (35), thus proving that the
algogenic effects of adenosine are independent of its vasodi-
lating action .
Study limitations. A critical issue in our study was the
choice of an appropriate dose of substance P . The
6ASPARDONE ET AL
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endothelium-dependent vasodilator effects of substance P
have been extensively investigated in humans on capaci-
tance and resistance peripheral vessels (7) and in the coro-
nary circulation (8-11) . The intracoronary infusion of
11 .2 pmol/min of substance P was found to cause maximal
coronary vasodilation within about 8 s in the absence of
systemic hemodynamic effects (8) . Therefore, in our study
this dose was infused for 3 min before adenosine infusion, on
the assumption that it was sufficient to produce maximal or
near-maximal stimulation of muscular and cardiac sensory
receptors . Another critical issue of our study was the assess-
ment of pain . To this end we used the visual analog scale .
This approach has been extensively validated by Huskisson
(16). Its reliability is confirmed by the observation in this and
in a previous study (35), that pain severity during infusion of
adenosine before and after placebo is similar . Finally, in this
study, testing personnel were not unaware of the nature of
the infused materials . However, the greatest effort was made
in following a very rigid protocol to avoid any potential bias .
In particular, all patients were reminded that they could
develop symptoms at the beginning of each infusion only,
and this request was not repeated during the infusion . The
patients themselves, who were unaware of the nature of the
infused materials, marked the visual analog scale .
Conclusions and clinical implications . This study shows
that the infusion of substance P causes muscular and cardiac
hyperalgesia, which might be particularly important in the
modulation of pain in the presence of tissue damage when
substance P is likely to be released by nerve endings . Under
these circumstances, substance P might amplify the well
known algogenic effects of adenosine .
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